Advocacy at a Glance STEVEN GROSSMAN 12/9/16 Advocacy at a Glance STEVEN GROSSMAN 12/9/16 Continuing Resolution Close, But May Not Make Friday Night Deadline Read More Analysis and Commentary STEVEN GROSSMAN 12/5/16 Analysis and Commentary STEVEN GROSSMAN 12/5/16 21st Century Cures Passes House -- with Pros and Cons Read More Advocacy at a Glance STEVEN GROSSMAN 12/5/16 Advocacy at a Glance STEVEN GROSSMAN 12/5/16 21st Century Cures Passes House; Set for Senate Vote Next Week Read More Analysis and Commentary STEVEN GROSSMAN 11/21/16 Analysis and Commentary STEVEN GROSSMAN 11/21/16 Significant Change Is Always Hard Read More Advocacy at a Glance STEVEN GROSSMAN 11/21/16 Advocacy at a Glance STEVEN GROSSMAN 11/21/16 Short-Term Continuing Resolution Likely Read More Analysis and Commentary STEVEN GROSSMAN 11/11/16 Analysis and Commentary STEVEN GROSSMAN 11/11/16 Ensuring and Advocating for an FDA that Works Read More Advocacy at a Glance STEVEN GROSSMAN 11/11/16 Advocacy at a Glance STEVEN GROSSMAN 11/11/16 Mr. Trump, the Election and FDA Read More Analysis and Commentary STEVEN GROSSMAN 11/7/16 Analysis and Commentary STEVEN GROSSMAN 11/7/16 Alliance Has No Prognosis for the Lame Duck Read More Advocacy at a Glance STEVEN GROSSMAN 11/7/16 Advocacy at a Glance STEVEN GROSSMAN 11/7/16 FDA and the Elections: Many Unknowns Read More Analysis and Commentary STEVEN GROSSMAN 10/28/16 Analysis and Commentary STEVEN GROSSMAN 10/28/16 Musical Chairs and Post-Election Congressional Committee Leadership Read More Advocacy at a Glance STEVEN GROSSMAN 10/28/16 Advocacy at a Glance STEVEN GROSSMAN 10/28/16 Down-Ballot Congressional Races: Another Post-Election Unknown Read More Analysis and Commentary STEVEN GROSSMAN 10/21/16 Analysis and Commentary STEVEN GROSSMAN 10/21/16 Plus ça Change, Plus c'est la Même Chose (or Maybe Not) Read More Advocacy at a Glance STEVEN GROSSMAN 10/21/16 Advocacy at a Glance STEVEN GROSSMAN 10/21/16 Presidential Transition Planning Underway Read More Analysis and Commentary STEVEN GROSSMAN 10/14/16 Analysis and Commentary STEVEN GROSSMAN 10/14/16 And Now Much Depends on Election Day Outcomes Read More Advocacy at a Glance STEVEN GROSSMAN 10/14/16 Advocacy at a Glance STEVEN GROSSMAN 10/14/16 Congress to Return November 14; Government Funding Top Priority Read More Advocacy at a Glance STEVEN GROSSMAN 10/1/16 Advocacy at a Glance STEVEN GROSSMAN 10/1/16 A CR Gets Passed ... But Has Fiscal Implications Read More Advocacy at a Glance STEVEN GROSSMAN 10/1/16 Advocacy at a Glance STEVEN GROSSMAN 10/1/16 CR through December 9 Passes; Congress in Recess Read More Analysis and Commentary STEVEN GROSSMAN 9/23/16 Analysis and Commentary STEVEN GROSSMAN 9/23/16 FDA Purchasing Power is on the Line Read More Advocacy at a Glance STEVEN GROSSMAN 9/23/16 Advocacy at a Glance STEVEN GROSSMAN 9/23/16 Continuing Resolution Still in Negotiations; One Week to Go or Else Read More Analysis and Commentary STEVEN GROSSMAN 9/16/16 Analysis and Commentary STEVEN GROSSMAN 9/16/16 What to Expect When You are Expecting a Lame Duck Read More Newer Posts Older Posts
Advocacy at a Glance STEVEN GROSSMAN 12/9/16 Advocacy at a Glance STEVEN GROSSMAN 12/9/16 Continuing Resolution Close, But May Not Make Friday Night Deadline Read More
Analysis and Commentary STEVEN GROSSMAN 12/5/16 Analysis and Commentary STEVEN GROSSMAN 12/5/16 21st Century Cures Passes House -- with Pros and Cons Read More
Advocacy at a Glance STEVEN GROSSMAN 12/5/16 Advocacy at a Glance STEVEN GROSSMAN 12/5/16 21st Century Cures Passes House; Set for Senate Vote Next Week Read More
Analysis and Commentary STEVEN GROSSMAN 11/21/16 Analysis and Commentary STEVEN GROSSMAN 11/21/16 Significant Change Is Always Hard Read More
Advocacy at a Glance STEVEN GROSSMAN 11/21/16 Advocacy at a Glance STEVEN GROSSMAN 11/21/16 Short-Term Continuing Resolution Likely Read More
Analysis and Commentary STEVEN GROSSMAN 11/11/16 Analysis and Commentary STEVEN GROSSMAN 11/11/16 Ensuring and Advocating for an FDA that Works Read More
Advocacy at a Glance STEVEN GROSSMAN 11/11/16 Advocacy at a Glance STEVEN GROSSMAN 11/11/16 Mr. Trump, the Election and FDA Read More
Analysis and Commentary STEVEN GROSSMAN 11/7/16 Analysis and Commentary STEVEN GROSSMAN 11/7/16 Alliance Has No Prognosis for the Lame Duck Read More
Advocacy at a Glance STEVEN GROSSMAN 11/7/16 Advocacy at a Glance STEVEN GROSSMAN 11/7/16 FDA and the Elections: Many Unknowns Read More
Analysis and Commentary STEVEN GROSSMAN 10/28/16 Analysis and Commentary STEVEN GROSSMAN 10/28/16 Musical Chairs and Post-Election Congressional Committee Leadership Read More
Advocacy at a Glance STEVEN GROSSMAN 10/28/16 Advocacy at a Glance STEVEN GROSSMAN 10/28/16 Down-Ballot Congressional Races: Another Post-Election Unknown Read More
Analysis and Commentary STEVEN GROSSMAN 10/21/16 Analysis and Commentary STEVEN GROSSMAN 10/21/16 Plus ça Change, Plus c'est la Même Chose (or Maybe Not) Read More
Advocacy at a Glance STEVEN GROSSMAN 10/21/16 Advocacy at a Glance STEVEN GROSSMAN 10/21/16 Presidential Transition Planning Underway Read More
Analysis and Commentary STEVEN GROSSMAN 10/14/16 Analysis and Commentary STEVEN GROSSMAN 10/14/16 And Now Much Depends on Election Day Outcomes Read More
Advocacy at a Glance STEVEN GROSSMAN 10/14/16 Advocacy at a Glance STEVEN GROSSMAN 10/14/16 Congress to Return November 14; Government Funding Top Priority Read More
Advocacy at a Glance STEVEN GROSSMAN 10/1/16 Advocacy at a Glance STEVEN GROSSMAN 10/1/16 A CR Gets Passed ... But Has Fiscal Implications Read More
Advocacy at a Glance STEVEN GROSSMAN 10/1/16 Advocacy at a Glance STEVEN GROSSMAN 10/1/16 CR through December 9 Passes; Congress in Recess Read More
Analysis and Commentary STEVEN GROSSMAN 9/23/16 Analysis and Commentary STEVEN GROSSMAN 9/23/16 FDA Purchasing Power is on the Line Read More
Advocacy at a Glance STEVEN GROSSMAN 9/23/16 Advocacy at a Glance STEVEN GROSSMAN 9/23/16 Continuing Resolution Still in Negotiations; One Week to Go or Else Read More
Analysis and Commentary STEVEN GROSSMAN 9/16/16 Analysis and Commentary STEVEN GROSSMAN 9/16/16 What to Expect When You are Expecting a Lame Duck Read More
